3,5-二氯-4-甲基吡啶 | 100868-46-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3,5-二氯-4-甲基吡啶
• 英文名称: 3,5-dichloro-4-picoline
• 英文别名: 3,5-dichloro-4-methyl-pyridine；3,5-Dichloro-4-methylpyridine
• CAS: 100868-46-0
• 化学式: C₆H₅Cl₂N
• mdl: MFCD09839290
• 分子量: 162.018
• InChiKey: YBHYECGRNFZJPC-UHFFFAOYSA-N

物化性质

• 熔点：
  49 °C
• 沸点：
  125-127 °C(Press: 74 Torr)
• 密度：
  1.319±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  应存于室温、密封、干燥处。

反应信息

• 作为反应物：
  描述：

  3,5-二氯-4-甲基吡啶 在 三氯化硼 、 potassium carbonate 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 52.5h， 生成 2-{6-[2-(3,5-dichloropyridin-4-yl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide
  参考文献：
  名称：

  Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis

  摘要：

  Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammatory drugs has been going on for decades. However, only roflumilast has received FDA approval. One key challenge has been the low therapeutic window observed in the dinic for PDE4 inhibitors, primarily due to PDE4 mediated side effects. Here we describe our approach to circumvent this issue by applying a soft-drug concept in the design of a topically acting PDE4 inhibitor for treatment of dermatological diseases. We used a fast follower approach, starting from piclamilast. In particular, simultaneous introduction of 2'-alkoxy substituents and changing an amide to a keto linker proved to be beneficial when designing potential soft-drug candidates. This effort culminated in identification of LEO 29102 (20), a potent, selective, and soft-drug PDE4 inhibitor with properties suitable for patient-friendly formulations giving efficient drug delivery to the skin. Compound 20 has reached phase 2 and demonstrated clinically relevant efficacy in the treatment of atopic dermatitis.

  DOI：

  10.1021/jm500378a
• 作为产物：
  描述：

  碘甲烷 在 正丁基锂 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 以68%的产率得到3,5-二氯-4-甲基吡啶
  参考文献：
  名称：

  Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors

  摘要：

  该发明涉及磷酸二酯酶4（PDE4）酶的抑制剂。更具体地，该发明涉及1-苯基-2-吡啶基烷基醇衍生物化合物，制备这种化合物的方法，含有它们的组合物以及它们的治疗用途。

  公开号：

  US20080015226A1
• 作为试剂：
  描述：

  3,5-二氯-4-甲基吡啶 、 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzoic acid methyl ester 在 3,5-二氯-4-甲基吡啶 作用下， 以90.5的产率得到1-(3-(环丙基甲氧基)-4-(二氟甲氧基)苯基)-2-(3,5-二氯-1-吡啶-4-基)乙酮
  参考文献：
  名称：

  PROCESS FOR THE PREPARATION OF A PDE4 INHIBITOR

  摘要：

  本发明涉及一种制备具有磷酸二酯酶（PDE4）抑制活性的化合物（I）的过程。该发明还涉及通过结晶分离化合物（I）的过程，以及将其与适当载体或载体组合用于制备吸入药物组合物的过程。本发明还涉及化合物（I）的溶剂化合物和晶体形式。合成的产品适用于制药应用，例如用于治疗呼吸系统疾病。

  公开号：

  US20150111931A1

文献信息

• [EN] 4-METHOXYACRIDINE-1-CARBOXAMIDE DERIVATIVES AND THE PHENAZINE AND OXANTHRENE ANALOGS AS PDE4-INHIBITORS FOR THE TREATMENT OF ASTHMA AND CHRONIC PULMONARY DISEASE (COPD)<br/>[FR] DERIVES DE 4-METHOXYACRIDINE-1-CARBOXAMIDE ET LES ANALOGUES PHENAZINE ET OXANTHRENE UTILISES COMME INHIBITEURS PDE4 POUR LE TRAITEMENT DE L'ASTHME ET LA MALADIE PULMONAIRE CHRONIQUE (COPD)
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2006040650A1

  公开（公告）日：2006-04-20

  The present invention relates to new Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) for treatment of asthma: Ar is a substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic ring or substituted or unsubstituted heteroaryl ring; each occurrence of L is O, S or NR3; X and A are independently -CRaRb -, -CRa-, -C(=B)-, O, S(O)m, N or NR3; each occurrence of m is 0, 1, or 2; n is 0-4; p is 0-2; Y is -C(=B)C(=D)NR4 or -C(=B)NR4 B is O, S or NRa; D is O, S or NRa; The other substituents are defined in the claims.

  本发明涉及用于治疗哮喘的新磷酸二酯酶4型（PDE4）抑制剂的化学式（1）：Ar是取代或未取代的芳基，取代或未取代的芳基烷基，取代或未取代的杂环环或取代或未取代的杂芳环；每次出现的L是O、S或NR3；X和A独立地是-CRaRb-，-CRa-，-C(=B)-，O，S(O)m，N或NR3；每次出现的m是0、1或2；n为0-4；p为0-2；Y是-C(=B)C(=D)NR4或-C(=B)NR4；B是O、S或NRa；D是O、S或NRa；其他取代基在权利要求中定义。
• JANUS KINASE INHIBITOR COMPOUNDS AND METHODS
  申请人：GOODACRE SIMON CHARLES

  公开号：US20100317643A1

  公开（公告）日：2010-12-16

  The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R 1 , R 2 , R 4 and R 5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof

  这项发明提供了公式I的化合物，其立体异构体或药学上可接受的盐，其中A、B、D、R1、R2、R4和R5在此处被定义，包括公式I化合物的药物组合物以及其使用方法
• Phthalazine derivatives phosphodiesterase 4 inhibitors
  申请人：Zambon Group S.p.A.

  公开号：US06329370B1

  公开（公告）日：2001-12-11

  The present invention provides a compound selected from the group including: 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-4-phenyl-phthalazine; 4-(3,5-dichloro-pyridin-4-ylmethyl)-7-methoxy-1H-phthalazin-2-carboxylic acid methyl ester; benzyl-{3-{1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-phthalazin-5-yl}-prop-2-ynyl}-methyl-amine; 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-5-(5-morpholin-4-yl-pent-1-ynyl)-phthalazine dihydrochloride; 3-{1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-phthalazin-5-yl}-prop-2-yn-1-ol; 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-4-morpholin-4-yl-phthalazine; 1-(3,5-dichloro-pyridin-4-ylmethyl)-6-methoxy-4-(1,2,4)triazol-1-yl-phthalazine; N→O derivatives thereof; and pharmaceutically acceptable salts thereof. The invention also provides a pharmaceutical composition which includes a therapeutically effective amount of the above compound in admixture with a suitable carrier.

  本发明提供了一种从以下组中选择的化合物：1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-4-苯基-酞嗪；4-(3,5-二氯-吡啶-4-基甲基)-7-甲氧基-1H-酞嗪-2-羧酸甲酯；苄基-{3-{1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-酞嗪-5-基}-丙-2-炔基}-甲基-胺；1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-5-(5-吗啉-4-基-戊-1-炔基)-酞嗪二氢氯酸盐；3-{1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-酞嗪-5-基}-丙-2-炔-1-醇；1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-4-吗啉-4-基-酞嗪；1-(3,5-二氯-吡啶-4-基甲基)-6-甲氧基-4-(1,2,4)三唑-1-基-酞嗪；其N→O衍生物；及其药用可接受盐。本发明还提供了一种药物组合物，包括与适宜载体混合的上述化合物的治疗有效量。
• [EN] 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION<br/>[FR] DÉRIVÉS DE 2-AMINO-BENZIMIDAZOLE UTILES DANS LE TRAITEMENT D'INFLAMMATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012076672A1

  公开（公告）日：2012-06-14

  This invention relates to compounds of formula (I), their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the 10 treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R3, R4, R6, R2,R7, R8, R9, Ra, Rb have meanings given in the description.

  本发明涉及公式（I）的化合物，它们作为微体前列腺素E2合酶-1（mPGES-1）的抑制剂的使用，包含它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病及相关状况的药物的使用。A、M、W、R1、R2、R3、R4、R6、R2、R7、R8、R9、Ra、Rb的含义在描述中给出。
• Derivatives of benzofuran or benzodioxole
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US06514996B2

  公开（公告）日：2003-02-04

  An oxygen-containing heterocyclic compound represented by following Formula (I): wherein R1 and R2 independently represent hydrogen, lower alkyl, cyano, —(CH2)n—E1—CO—G1 (wherein E1 represents a bond, O, or NH; and G1 represents hydrogen, substituted or unsubstituted lower alkyl, OR6, or NR7R8; and n represents an integer of 0 to 4), or the like; R1 and R2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R2, and R11 or R13 described below are combined to form a single bond; R3 represents hydrogen, phenyl, or halogen; R4 represents hydroxy, lower alkoxy, or the like; A represents —C(R9)(R10)— or O; B represents O, NR11, —C(R12)(R13)—, or —C(R14)(R15)—C(R16)(R17)—; D represents (i) —C(R18)(R19)—X— (wherein X represents —C(R21)(R22)—, S, or NR23), (ii) —C(R19a)═Y— [Y represents —C(R24)—Z— (wherein Z represents CONH, CONHCH2, or a bond), or N], or (iii) a bond; and R5 represents aryl, an aromatic heterocyclic group, cycloalkyl, pyridine-N-oxide, cyano, or lower alkoxycarbonyl; or pharmaceutically acceptable salts thereof.

  根据您的要求，以下是该化学公式（I）的中文翻译： 一个含氧杂环化合物，由以下公式（I）表示：其中R1和R2独立代表氢、低级烷基、氰基、—(CH2)n—E1—CO—G1（其中E1代表一个键、O或NH；G1代表氢、取代或未取代的低级烷基、OR6或NR7R8；n代表0到4的整数），或类似物；R1和R2共同代表与相邻碳原子一起的饱和碳环；或者R2与下面描述的R11或R13结合形成一个单键；R3代表氢、苯基或卤素；R4代表羟基、低级烷氧基或类似物；A代表—C(R9)(R10)—或O；B代表O、NR11、—C(R12)(R13)—或—C(R14)(R15)—C(R16)(R17)—；D代表（i）—C(R18)(R19)—X—（其中X代表—C(R21)(R22)—、S或NR23）、（ii）—C(R19a)═Y— [Y代表—C(R24)—Z—（其中Z代表CONH、CONHCH2或一个键）或N]，或（iii）一个键；R5代表芳基、芳香杂环基、环烷基、吡啶-N-氧化物、氰基或低级烷氧基甲酸；或其药物可接受的盐。